IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 5, Issue 1, October 2025

Impact Factor: 7.53

Artificial Intelligence-Driven Design and Optimization of Micro needle-Based Drug Delivery Systems: A Review

Jyoti Yadav[1], Deepika Gupta[2], Mahavir Chhajed[1], Abhimanyu S. Rathore[1]

Department of Pharmaceutics, Oxford International College, Indore[1]

University Institute of Pharmacy, Oriental University Indore[2]

Abstract: *Microneedle-based drug delivery systems have emerged as a promising transdermal technology capable of overcoming the limitations of conventional drug administration methods. These micron-scale needlescreate microchannels inthe skin, enabling painlessand efficient deliveryof therapeutic agents such as vaccines, proteins, peptides, and small-molecule drugs. However, the design, fabrication, and optimization of microneedle systems involve multiple parameters, including needle geometry, material properties, drug loading, and release kinetics. Artificial intelligence (AI) has recently gained attention as a powerful tool for improving pharmaceutical formulation development and device design. AI techniques such as machine learning, deep learning, and predictive modeling can analyze large datasets and predict optimal formulation parameters, drug diffusion profiles, and skin permeation behavior. This review discusses the integration ofartificial intelligence in microneedle-based drug delivery systems, focusing on AI- driven design, formulation optimization, predictive modeling, and manufacturing processes. Additionally, current challenges, regulatory considerations, and future prospects of AI-enabled microneedle technologies are highlighted. The combination of AI with microneedle technology has the potential to accelerate pharmaceutical development, enhance drug delivery efficiency,and facilitate personalized transdermal therapies..*

Keywords: Artificial Intelligence, Microneedles, Drug Delivery, Machine Learning, Transdermal Systems, Pharmaceutical Optimization

I. INTRODUCTION

Transdermal drug delivery systems (TDDS) have attracted considerable interest due to their ability to provide controlled drug release, avoid first-pass metabolism, and improve patient compliance. However, the outermost layer of the skin, the stratum corneum, acts as a strong barrier that limits drug permeation and restricts the number of drugs that can be effectively delivered through the skin [1,2].

Microneedle technology has emerged as an innovative approach to overcome this barrier by creating microscopic channels in the skin without causing pain or significant tissue damage. These micro-scale needles penetrate the stratum corneum and facilitate the delivery of drugs directly into the epidermis or dermis, thereby enhancing drug permeation and bioavailability[3]. Microneedles canbe fabricated froma varietyofmaterials suchas metals, polymers, silicon, and biodegradable materials, and they have been widely investigated for the delivery of vaccines, peptides, proteins, and small-molecule drugs [3,4].

Despite the promising potential of microneedle systems, their development involves numerous formulation variables and design parameters such as needle geometry, material selection, drug loading, and release kinetics. Traditional formulation approaches rely heavily on trial-and-error experimentation, which is time-consuming and costly. Artificial intelligence (AI) and machine learning technique useprovidepowerfull data-driventools that canpredict formulationperformance, optimize design parameters, and accelerate the development process of advanced drug delivery systems.

DOI: 10.48175/IJARSCT-29200L

The integration of AI into pharmaceutical research has opened new opportunities for improving formulation design, predicting drug permeation, and optimizing transdermal delivery technologies. AI-based modeling approaches can analyze large experimental datasets to identify optimal formulation conditions and enhance the efficiency and precision of microneedle-based drug delivery systems.

II. MICRONEEDLE-BASED DRUG DELIVERY SYSTEMS

Concept of Microneedles

Microneedlesare micron-scale needle structuresdesignedto penetratethe stratumcorneum,the outermost barrieroftheskin, anddelivertherapeuticagentsdirectintotheepidermisordermis. These micro-projectionscreatetransient and minimally invasive microchannel

Sthat facilitatesthe diffusion of drug molecules across the skin barrier without causing significant pain or bleeding. The typical length of microneedles ranges from 50 to 900 µm, which allows them to bypass the stratum corneum while avoiding stimulation of deeper dermal nerves [5].

Microneedle technology has gained considerable attention as a minimally invasive alternative to conventional hypodermic injectionsand traditionaltransdermalpatches. This approach improves drug permeability, enhances bioavailability, and enables the deliveryof macromolecules such as proteins, peptides, vaccines, and nucleic acids that normally cannot cross the skin barrier [6].

Types of Microneedles

Microneedles are broadly classified based on their structure, mechanism of drug delivery, and material composition. The major types include the following:

1. Solid Microneedles

Solid microneedles are primarily used to create microchannels in the skin through a process known as "poke-and-patch." After the microneedles puncture the stratum corneum, a drug formulation such as a gel, cream, or transdermal patch is applied over the treated area to allow drug diffusion through the microchannels [7].

2. Coated Microneedles

Coated microneedles are fabricated by applying a thin layer of drug onto the surface of solid microneedles. Upon insertion into the skin, the drug coating dissolves rapidly and releases the therapeutic agent into the epidermal layers. This method is particularly useful for rapid drug delivery and vaccine administration [8].

3. Dissolving Microneedles

Dissolving microneedles are prepared using biodegradable and water-soluble polymers such as polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), or hyaluronic acid. After insertion intothe skin, the microneedles dissolve and release the encapsulated drug, eliminating the risk of sharp biohazardous waste and improving patient safety [9].

4. Hollow Microneedles

Hollow microneedles contain internal microchannels that allow liquid drug formulations to be injected directly into the skin layers. These microneedles function similarly to conventional hypodermic needles but at a muchsmaller scale, enabling controlled infusionofdrugs, vaccines, or biologics [6].

5. Hydrogel-Forming Microneedles

Hydrogel-forming microneedles are composed of cross-linked polymer networks that absorb interstitial fluid from the skin after insertion. This swelling process forms a hydrogel matrix through which drugs can diffuse from an attached reservoir into the skin in a controlled manner [10].

III. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICALSCIENCES

Artificial intelligence (AI) refers to a group of computational technologies designed to simulate human intelligence and perform tasks such as learning, pattern recognition, prediction, and decision-making. AI systems can process large datasets, identify hidden relationships between variables, and generate predictive models that support scientific and industrial decision-making. Inrecent years, AI has become an importanttoolinpharmaceuticalresearch, particularly indrug discovery, formulation design, process optimization, and personalized medicine [11].

In pharmaceutics, AI techniques are increasingly applied to analyze complex formulation data, predict drug release behavior, and optimize drug delivery systems. These approaches enable researchers to model nonlinear relationships between formulation variables and product performance, therebyreducingexperimentalworkloadandacceleratingformulationdevelopment [12].

SeveralAI techniquesarecommonly Sedinpharmaceuticalsciences:

• MachineLearning (ML)

Machine learning algorithms learn patterns from experimental data and develop predictive modelswithoutbeingexplicitlyprogrammed.MLhasbeen applied predictdrugsolubility, permeability, stability, and formulation performance [13].

• DeepLearning(DL)

Deep learning isasubsetofmachine learning that utilizesmultilayerneuralnetworkstoanalyze large and complex datasets. It has shown great potential in pharmaceutical image analysis, molecular modeling, and advanced formulation prediction [14].

• ArtificialNeuralNetworks (ANN)

Artificial neural networks are computational models inspired by the structure of biological neurons. ANNsarewidelyused inpharmaceuticstomodelnonlinearrelationshipsinformulation optimization, drug release prediction, and pharmacokinetic analysis [15].

• Support VectorMachines (SVM)

Support vector machines are supervised learning algorithms used for classification and regressionanalysis. Inpharmaceuticalapplications, SVMmodelsareused forpredictingdrug– excipient compatibility, drug permeability, and formulation stability [13].

• RandomForest Algorithms

Randomforest isan ensemble machine learning methodthatcombines multipledecisiontrees to improve predictive accuracy and reduce overfitting. This algorithm has been applied to predict formulationparameters, drug deliveryefficiency, and pharmaceuticalprocess optimization [14].

These AI-based tools enable researchers to analyze complex datasets and identify relationships between formulation variables and drug delivery outcomes. Consequently, AI is becoming a powerfulapproach for accelerating pharmaceuticaldevelopment and improving the efficiencyof drug delivery system design [11–15].

IV. AI-DRIVEN DESIGN OF MICRONEEDLE SYSTEMS

Artificial intelligence has emerged as a powerful tool for optimizing the design and performance of microneedle-based drug delivery systems. The design of microneedles involves multiple parameters that influencedrugpermeation, mechanicalstrength,andpatient safety. Conventional experimental optimization methods are often time-consuming and require extensive laboratory trials. AI-based computational models can analyze large datasets and identify the optimal combination of design variables for improved microneedle performance [16].

AI algorithms can be applied to optimize several critical microneedle design parameters, including:

• Needlelength– Determinesthedepthofskinpenetrationand drug deliveryefficiency.
• Needledensity–Influencesthenumberofmicrochannelsformed intheskinandtheamount of drug delivered.
• Needletipsharpness–Affectspenetrationforceandinsertionefficiency.

• Materialproperties–Includes polymercomposition, biodegradability,anddrug compatibility.
• Mechanicalstrength –Ensures that microneedlescanpenetratetheskinwithoutbendingor breaking.

Machine learning models such as artificial neural networks, support vector machines, and regression algorithms can predict the penetration efficiency and mechanical stability of microneedles based on design parameters and material characteristics. These predictive models allow researchers to simulate microneedle performance before conducting experimental studies, significantly reducing development time and cost [17].

Furthermore, AI-driven optimization techniques can assist in selecting suitable fabrication materialsandpredictingdrugreleaseprofilesfromdissolvingorhydrogel-forming microneedles. By integrating computational modeling with experimental data, AI can accelerate the development of safe, efficient, and patient-friendly microneedle drug delivery systems [18].

V. AI-BASED OPTIMIZATION OF MICRONEEDLE FORMULATIONS

Artificial intelligence plays an important role in optimizing the formulation parameters of microneedle-based drug delivery systems. The formulation of microneedles involves multiple variablesthat influencedrugloading, mechanicalstability, dissolutionbehavior, anddrugrelease characteristics. Conventional optimization methods require numerous experimental trials to determine the optimal formulation composition. AI-based approaches enable the analysis of complex datasets and provide predictive models that can efficiently optimize formulation parameters [19].

AItechniquesheoptimizeseveralimportantformulationparameters,including:

• Polymerconcentration–Influencesmicroneedlemechanicalstrength, dissolutionbehavior, and drug release characteristics.
• Drugloadingefficiency–Determinestheamountoftherapeuticagent incorporatedwithinthe microneedle matrix.
• Dissolutionrate–Affectsthespeedat whichdissolving microneedlesrelease then capsulated drug after insertion into the skin.
• Mechanicalstrength–Ensures that microneedlesmaintain structure alintegrityduringskin penetration.
• Skin permeation–Determinestherateandextentofdrug transportthroughtheskin layers.

Artificial neural networks (ANNs) and other machine learning algorithms can predict the influence of these formulation variables on drug release profiles and permeation characteristics. These models analyze experimental data to identify relationships between formulation composition and performance outcomes, enabling researchers to determine optimal formulation conditions with fewer laboratory experiments [20].

Furthermore, AI-driven optimization methods can simulate drug release kinetics and predict formulationstabilityunderdifferentconditions.Thispredictivecapabilitysignificantly
Acceleratesformulationdevelopment, reduces costs, and improves the efficiencyofmicroneedle- based drug delivery systems [21].

VI. AI-ASSISTED PREDICTION OF DRUG RELEASE AND SKIN PERMEATION

Artificial intelligence has become an effective tool for predicting drug release behavior and skin permeation characteristics in microneedle-based transdermal drug delivery systems. The release and permeation of drugs through the skin depend on multiple factors such as microneedle geometry, polymer composition, drug physicochemical properties, and skin barrier characteristics. AI-based predictive models can analyze large experimentaldatasets and simulate the complex interactions betweenthese variables, therebyimproving the accuracyof formulation design and reducing the need for extensive laboratory experiments [22].

Predictive models based on AI can simulate several important processes involved in transdermal drug delivery, including:

• Drugdiffusionthroughmicroneedlechannels –AI modelscanestimatetherateatwhich drugs diffuse through the microchannels created by microneedles in the skin.
• Drugreleasekinetics–Machine learningalgorithmscanpredicttherateandpatternofdrug release from dissolving or hydrogel-forming microneedles.

• Skinpermeationprofiles–AItechniquescan modeldrugtransport acrossdifferent layers of the skin, including the epidermis and dermis.

• Pharmacokineticbehavior–Predictivealgorithmscanestimatesystemicdrugabsorptionand plasma concentration profiles following transdermal administration.

Artificial neural networks, regression models, and deep learning approaches are widely used to analyze experimental drug release data and develop predictive models for transdermal drug delivery systems. These computational approaches help researchers understand complex formulation–performance relationships and identify optimal design parameters for efficient drug delivery [23].

By integrating AI with experimental pharmacokinetic and permeation data, researchers can design more efficient microneedle-based transdermal systems that provide controlled and sustained drug delivery. This approach significantly accelerates product development and improves the therapeutic performance of transdermal drug delivery technologies [24].

VII. AI IN MANUFACTURING OF MICRONEEDLE SYSTEMS

Artificial intelligence technologiesare increasinglybeing applied inthe manufacturing processes of microneedle-based drug delivery systems. The fabrication of microneedle arrays requires precise control of multiple process parameters, including temperature, pressure, material composition, and molding conditions. Traditional manufacturing methods may face challenges suchas variability in microneedle dimensions, defects in needle structures, and inconsistent drug loading. AI-driven manufacturing approaches can monitor and analyze real-time production data to improve process efficiency and product quality [25].

AI technologies can significantly improve manufacturing processes by performing several important functions, including:

• Monitoring production parameters – AI systems can track and analyze critical manufacturing variables such as temperature, pressure, and polymer viscosity duringmicroneedle fabrication.

• Detectingdefectsin microneedle arrays– Machine learningalgorithmscombinedwithimage analysis techniques can identify defects such as broken needles, irregular shapes, or incomplete structures in microneedle arrays.

• Predicting process variations – AI models can analyze historical production data to predict potential variations in the manufacturing process and allow corrective actions before defects occur.

• Improving quality control – Automated AI-based quality control systems can evaluate microneedle geometry, mechanical strength, and drug loading uniformity to ensure consistent product performance.

The integration of AI with advanced manufacturing technologies such as 3D printing, microfabrication, and micro-molding techniques has further enhanced the precision and reproducibilityofmicroneedledevices. AI-assistedoptimizationoffabricationparametersallows the production of microneedles with uniform dimensions, improved mechanical strength, and reliable drug delivery performance. These technologies are expected to play a key role in the large-scale industrial manufacturing of microneedle-based transdermal systems [26,27].

VIII. APPLICATIONS OF AI-ENABLED MICRONEEDLE DRUG DELIVERY

AI-integratedmicroneedlesystemshavedemonstratedsignificant potentialinvarioustherapeutic and biomedical applications. By combining advanced microneedle technology with artificial intelligence–basedpredictive models, researcher scandesignefficient drugdeliverysystemswith improved therapeutic outcomes. AI tools help optimize microneedle design, drug loading, and delivery parameters, thereby expanding their application in several medical fields [28].

Vaccine Delivery

Microneedle patches have emerged as promising alternatives to conventional injections for vaccine administration. These patches can deliver vaccines painlessly into the skin, where a high concentration of immune cells is present, resulting in enhanced immune responses. AI-based optimizationtechniquescanhelp determine the optimalmicroneedle design, vaccine dosage, and release profile for improved immunization efficiency [29].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, October 2025 Impact Factor: 7.53

Diabetes Management

Microneedle-based systems have been explored for the transdermal delivery of insulin andforcontinuousglucosemonitoring.AIalgorithmscananalyzepatientdata,predict glucose.
fluctuations, and optimize insulin release from microneedle patches. Such smart microneedle systems may enable closed-loop drug delivery platforms for better diabetes management [30].

Cancer Therapy

Microneedle drug deliverysystems are also being investigated fortargeted deliveryofanticancer drugs. By delivering chemotherapeutic agents directly into tumor tissues or skin lesions, microneedles can reduce systemic toxicity and improve therapeutic effectiveness. AI-based modeling can assist in optimizing drug loading, release kinetics, and penetration efficiency for effective cancer treatment [31].

Cosmetic and Dermatological Treatments

Microneedles are widely used in dermatology and cosmetic treatments for the delivery of peptides, vitamins, antioxidants, and other bioactive compounds into the skin. AI-driven formulationoptimizationcan improvethepenetrationand stabilityofcosmeticagents, enhancing treatment outcomes for conditions such as skin aging, pigmentation disorders, and acne [32].

IX. CHALLENGES AND LIMITATIONS

Despite the significant advantages of integrating artificial intelligence into the development of microneedle-based drug delivery systems, several challenges and limitations still exist. The successful implementation of AI technologies in pharmaceutical research requires high-quality data, advanced computational infrastructure, and interdisciplinary collaboration. These factors can limit the widespread adoption of AI-driven approaches in microneedle development [33].

SomeofthemajorchallengesassociatedwithAI-basedmicroneedledevelopmentinclude:

• Limited availability of large experimental datasets – Machine learning algorithms require large and well-structured datasets for accurate model training. In many cases, microneedle formulation and performance data are limited or not standardized, which can reduce the reliability of AI predictions.

• High computational requirements – Advanced AI models, particularly deep learning algorithms, require significant computational power and specialized hardware. This can increase the cost and complexity of implementing AI systems in pharmaceutical research environments [34].

• Regulatory uncertainty for AI-driven systems – Regulatory agencies are still developing guidelines for evaluating AI-based pharmaceutical products and manufacturing processes. The lack of clear regulatory frameworks can slow the translation of AI-assisted microneedle technologies into clinical and commercial applications [35].

• Need for interdisciplinary expertise – The effective integration of AI in pharmaceutical sciences requires collaboration among experts in pharmaceutics, data science, materials science,
and biomedicalengineering. The shortageofprofessionalswithexpertise acrossthese disciplines may limit the implementation of AI-driven drug delivery research.

Addressing these challenges will be essential for maximizing the potential of AI technologies in microneedle-based drug delivery systems and ensuring their safe and effective translation into clinical practice [33–35].

X. FUTURE PERSPECTIVES

The integration of artificial intelligence with microneedle-based drug delivery systems is expected to significantly transform the field of transdermal therapeutics. As AI technologies continue to advance, they will play an increasingly important role in the design, optimization,and clinical application of microneedle systems. Future research is likely to focus on the development of intelligent and adaptive drug deliveryplatforms that can respond dynamically to physiological conditions and patient-specific needs [36].

Severalpromising directionsfor futureresearch include.

• AI-integrated smart microneedle patches – Advanced microneedle patches equipped with AI-based control systems may enable automated drug delivery based on patient-specific parameters and physiological responses.
• Real-time monitoring of drug delivery – Integration of AI algorithms with sensor technologies can allow continuous monitoring of drug release, skin permeation, and therapeutic effectiveness, enabling timely adjustments to the delivery system [37].
• Personalized transdermal therapy – AI-driven predictive models can analyze patient data such as age, metabolism, disease state, and skin characteristics to design personalized microneedle formulations and dosing strategies.
• Integration of wearable biosensors with microneedle systems – Combining microneedles with wearable biosensors and AI-based data analysis can enable closed-loop drug delivery systems capable of monitoring biomarkers and adjusting drug release in real time.
The combination of artificial intelligence with microneedle technology is expected to revolutionize transdermal drug delivery by improving precision, efficiency, and patient compliance. These advancements may lead to the development of next-generation smart therapeuticsystems withenhancedclinicaleffectivenessand improved healthcareoutcomes[38].

XI. CONCLUSION

Microneedle-based drug deliverysystems represent a promising alternative to conventional drug administration methods due to their minimally invasive nature, painless application, and enhanced drug permeation capability through the skin barrier. By creating microscopic channels in the stratum corneum, microneedles enable efficient transdermal delivery of a wide range of therapeutic agents including vaccines, peptides, proteins, and small-molecule drugs.
Artificial intelligence provides powerful computational tools for optimizing various aspects of microneedle systems, including designparameters, formulationdevelopment, and manufacturing processes. AI-driven predictive models such as machine learning and artificial neural networks can analyze complex datasets to predict drug release behavior, skin permeation characteristics, and mechanical performance of microneedles. These capabilities significantly reduce experimental workload, shorten development timelines, and improve the efficiency of drug delivery systems.
Furthermore, the integration of AI with advanced technologies such as smart sensors, wearable devices, and automated manufacturing platformsmayenable the development ofnext-generation microneedle systems capable of real-time monitoring and personalized drug delivery. Such intelligent systems have the potential to improve therapeutic outcomes and patient compliance in the management of chronic diseases.
Although several challenges remain, including limited datasets, computational complexity, and regulatory considerations, ongoing advancements in artificial intelligence and pharmaceutical engineering are expected to overcome these limitations. Consequently, AI-enabled microneedle drug delivery systems are likely to play a significant role in the future of transdermaltherapeutics and precision medicine.

REFERENCES

[1]. Ruan S., Zhang Y., Feng N. Microneedle-mediated transdermal nanodelivery systems: A review. Biomaterials Science. 2021;9:8065–8089.
[2]. Wu C., Yu Q., Huang C., et al. Microneedles as transdermal drug delivery system for enhancing skin disease treatment. Acta Pharmaceutica Sinica B. 2024.
[3]. Chen Y., Duan Y., Li M., et al. Research progress on the application of microneedle transdermal drug delivery system in dermatology. Therapeutic Medicine Research. 2022.
[4]. AiX.,etal.Advancedtransdermaldrugdeliverysystem:Acomprehensivereviewofmicroneedle technologies and applications. European Journal of Pharmaceutics and Biopharmaceutics. 2024.
[5]. PrausnitzM.R., LangerR.Transdermaldrugdelivery.NatureBiotechnology.2008;26:1261-1268.
[6]. Kim Y. C., Park J. H., Prausnitz M. R. Microneedles for drug and vaccine delivery. Advanced Drug Delivery Reviews. 2012;64:1547-1568.
[7]. Donnelly R. F., Singh T. R., Garland M. J., et al. Hydrogel-forming microneedles for enhanced transdermal drug delivery. Advanced Functional Materials. 2012;22:4879-4890.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, October 2025
Impact Factor: 7.53

[8]. Gill H. S., Priessnitz M. R. Coated microneedles for transdermal delivery. Journal of Controlled Release. 2007;117:227-237.

[9]. Ita K. Dissolving microneedles for transdermal drug delivery: Advances and challenges. Drug Delivery and Translational Research. 2017;7:757-769.

[10]. Donnelly R. F., Mooney K., McCrudden M. T., et al. Hydrogel-forming microneedles: A review of materials and applications. Drug Delivery and Translational Research. 2014;4:165-176.

[11]. Mak K. K., Pichika M. R. Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today. 2019;24(3):773-780.

[12]. Vamathevan J., Clark D., Czodrowski P., et al. Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery. 2019;18:463-477.

[13]. Patel L.,Shukla T., HuangX.,UsseryD.W., WangS.Machinelearningmethodsindrug discovery. Molecules. 2020;25:5277.

[14]. Paul D., Sanap G., Shenoy S., et al. Artificial intelligence in drug discovery and development.Drug Discovery Today. 2021;26(1):80-93.

[15]. Agatonovic-Kustrin S., Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. Journal of Pharmaceutical and Biomedical Analysis. 2000;22:717-727.

[16]. Larrañeta E., Lutton R. E., Woolfson A. D., Donnelly R. F. Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. Materials Science and Engineering R. 2016;104:1-32.

[17]. Waghule T., Singhvi G., Dubey S. K., et al. Microneedles: A smart approach and increasing potential for transdermal drug delivery system. Biomedicine & Pharmacotherapy. 2019;109:1249-1258.

[18]. Kankala R. K., Xu X. M., Liu C. G., Chen A. Z., Wang S. B. Artificial intelligence and machine learning in drug delivery systems. Advanced Drug Delivery Reviews. 2022;182:114114.

[19]. Agatonovic-Kustrin S., Beresford R. Basic concepts of artificial neural network modeling and its application in pharmaceutical research. Journal of Pharmaceutical and Biomedical Analysis. 2000;22:717–727.

[20]. Kankala R. K., Xu X. M., Liu C. G., Chen A. Z., Wang S. B. Artificial intelligence and machine learning in drug delivery systems. Advanced Drug Delivery Reviews. 2022;182:114114.

[21]. Paul D., Sanap G., Shenoy S., et al. Artificial intelligence in drug discovery and pharmaceutical formulation development. Drug Discovery Today. 2021;26(1):80–93.

[22]. Kankala R. K., Xu X. M., Liu C. G., Chen A. Z., Wang S. B. Artificial intelligence and machine learning in drug delivery systems. Advanced Drug Delivery Reviews. 2022;182:114114.

[23]. Agatonovic-Kustrin S., Beresford R. Basic concepts of artificial neural network modeling and its application in pharmaceutical research. Journal of Pharmaceutical and Biomedical Analysis. 2000;22:717–727.

[24]. Vamathevan J., Clark D., Czodrowski P., et al. Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery. 2019;18:463–477.

[25]. Kankala R. K., Xu X. M., Liu C. G., Chen A. Z., Wang S. B. Artificial intelligence and machine learning in drug delivery systems. Advanced Drug Delivery Reviews. 2022;182:114114.

[26]. Daly R.,Harrington T. S.,Martin G. D.,HutchingsI. M.Inkjetprinting for pharmaceutics and drug delivery. International Journal of Pharmaceutics. 2015;494:554–567.

[27]. Larrañeta E., McCrudden M. T., Courtenay A. J., Donnelly R. F. Microneedles: A new frontier in transdermal drug delivery systems. Pharmaceutical Research. 2016;33:1055–1073.

[28]. Kankala R. K., Xu X. M., Liu C. G., Chen A. Z., Wang S. B. Artificial intelligence and machine learning in drug delivery systems. Advanced Drug Delivery Reviews. 2022;182:114114.

[29]. Kim Y. C., Park J. H., Prausnitz M. R. Microneedles for drug and vaccine delivery. Advanced Drug Delivery Reviews. 2012;64:1547–1568.

[30]. ItaK.Transdermaldeliveryofinsulinusingmicroneedles:Currentprogressandfutureprospects. Drug Delivery and Translational Research. 2017;7:757–769.

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 5, Issue 1, October 2025

Impact Factor: 7.53

[31]. LarrañetaE.,Lutton R. E.,Woolfson A. D.,Donnelly R.F. Microneedle arrays as transdermal drug delivery systems. Materials Science and Engineering R. 2016;104:1–32.

[32]. Donnelly R. F., Singh T. R., Garland M. J., et al. Hydrogel-forming microneedles for enhanced transdermal drug delivery. Advanced Functional Materials. 2012;22:4879–4890.

[33]. Mak K. K., Pichika M. R. Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today. 2019;24(3):773–780.

[34]. PaulD.,SanapG.,ShenoyS.,etal.Artificialintelligenceindrugdiscoveryanddevelopment. Drug Discovery Today. 2021;26(1):80–93.

[35]. Vamathevan J., Clark D., Czodrowski P., et al. Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery. 2019;18:463–477.

[36]. KankalaR.K.,XuX.M.,LiuC.G.,ChenA.Z.,WangS.B.Artificialintelligenceandmachine learning in drug delivery systems. Advanced Drug Delivery Reviews. 2022;182:114114.

[37]. Paul D., Sanap G., Shenoy S., et al. Artificial intelligence in drug discovery and pharmaceuticaldevelopment. Drug Discovery Today. 2021;26(1):80–93.

[38]. Vamathevan J., Clark D., Czodrowski P., et al. Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery. 2019;18:463–477